Search clinical trials for: HIV preventive vaccine

Total 23144 results

National Institute of Allergy and Infectious Diseases...

Completed

HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers

HIV Infections | Healthy

United States
ANRS, Emerging Infectious Diseases

Terminated

Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials

HIV Infection | HIV Seronegativity

France
St. Jude Children's Research Hospital

Terminated

Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults

HIV Infections

United States
Hospital Clinic of Barcelona

Completed

Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B

HIV Infections

Spain
Barbara Ensoli, MD
Novartis Vaccines

Terminated

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

HIV Infection

Italy
National Institute of Allergy and Infectious Diseases...

Completed

Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru (HVTN 914)

HIV Infections | Acquired Immunodeficiency Syndrome | RNA Virus Infections | Virus Diseases | Sexually Transmitted Diseases, Viral | Sexually Transmitted Diseases | Lentivirus Infections | Retroviridae Infections | Immunologic Deficiency Syndromes | Immune System Diseases | Slow Virus Diseases
Merck Sharp & Dohme LLC

Completed

Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)

HIV Infections | HIV
National Institute of Allergy and Infectious Diseases...

Withdrawn

HIV-1 Vaccine Test in Uninfected Adult Volunteers

Healthy

United States
University of British Columbia
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR)

Completed

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV

HIV Infections | H1N1 Influenza

Canada
Hospital Clinic of Barcelona

Completed

A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART (2009-016578-34)

HIV Infection

Spain
Merck Sharp & Dohme LLC
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Completed

A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)

HIV Infections | HIV-1
Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

HIV Infections | HIV-1
Bavarian Nordic

Completed

Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection

HIV Infections

Germany
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); EuroVacc Foundation

Completed

Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults

HIV Infections

Switzerland
Juan A. Arnaiz

Completed

A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection (RisVac02)

HIV Infections

Spain
International AIDS Vaccine Initiative
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

HIV Infections

Kenya, Zambia, Uganda
International AIDS Vaccine Initiative
University of Rochester; Aaron Diamond AIDS Research Center

Completed

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Prepare for Future HIV Vaccine Studies

HIV Infections

Haiti, Peru
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm

HIV Infections | HIV Seronegativity

United States
AlphaVax, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Completed

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

HIV Infections

United States, South Africa
AlphaVax, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Completed

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

HIV Infections

United States, Botswana, South Africa
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.

Completed

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

HIV Infections

United States
International AIDS Vaccine Initiative
University of Rochester

Completed

A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers

HIV Infections | HIV

United States
International Vaccine Institute
Siriraj Hospital; Vaccine Technologies Inc.

Completed

Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults

Diarrhea | Cholera | Vibrio Infections

Thailand
Medical Research Council
European and Developing Countries Clinical Trials Partnership (EDCTP)

Completed

Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers (PedVacc001)

HIV Infections | HIV-1

Gambia
Medical Research Council
European and Developing Countries Clinical Trials Partnership (EDCTP)

Unknown

Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers (PedVacc002)

HIV Infections | HIV-1

Kenya
National Institute of Allergy and Infectious Diseases...

Completed

Development of a New HIV Vaccine

HIV Infections

United States
Rockefeller University
Bill and Melinda Gates Foundation; International AIDS Vaccine Initiative; Aaron... and other collaborators

Completed

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers (ADVAX-EP)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications

HIV Infections

United States, Puerto Rico
Istituto Superiore di Sanità

Completed

Observational Study of the Preventive Trial With HIV-1 Tat Protein (ISS OBS P-001)

Healthy Subjects

Italy
Istituto Superiore di Sanità

Completed

Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein (ISSP-001)

HIV Infections

Italy
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials

HIV Infections

United States, South Africa, Peru, Brazil
French National Agency for Research on AIDS and...
EuroVacc Foundation

Completed

Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers (EV03/ANRSVAC20)

HIV Infections

France, Switzerland
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Unknown

Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Unknown

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of the EnvPro HIV Vaccine in Healthy Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

HIV-1 Vaccine Test in Uninfected Adult Volunteers

Healthy | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Analysis of Immune Responses to HIV Vaccines

HIV Infections | Acquired Immunodeficiency Syndrome

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults

HIV Infections

Australia
Walter Reed Army Institute of Research (WRAIR)

Unknown

HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
United Biomedical

Completed

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.

Completed

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

HIV Infections

United States

Search clinical trials for: HIV preventive vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations